



Supplement Figure 4


4A Subgroup analysis based on ctDNA detection methods (DFS/RFS)




4B Subgroup analysis based on ctDNA detection methods (OS)



4C Subgroup analysis based on ctDNA detection methods (EFS)



4D Subgroup analysis based on ctDNA detection methods (PFS)



Supplement Figure 4 - Forest plots of studies demonstrating the association between circulating tumor DNA positivity and survival outcomes in solid cancer patients who received neoadjuvant treatment across different ctDNA detection methods. (A) Disease-free survival/recurrence-free survival in NGS and dPCR subgroups. (B) Overall survival in NGS and dPCR subgroups. (C) Event-free survival in NGS and dPCR subgroups. (D) Progression-free survival in NGS and dPCR subgroups. DFS/RFS, disease-free survival/recurrence-free survival; OS, overall survival; EFS, event-free survival; PFS, progression-free survival; HR, Hazard ratio; NGS, next-generation sequencing; dPCR, digital polymerase chain reaction.